CERETEC (technetium tc-99m exametazime) by GE HealthCare is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 1988.
Drug data last refreshed 9h ago · AI intelligence enriched 2d ago
CERETEC is a technetium Tc-99m radiopharmaceutical diagnostic agent used for brain imaging, particularly cerebral blood flow studies and detection of stroke, dementia, and other neurological conditions. It works by binding to red blood cells and emitting gamma radiation that is detected by imaging equipment to visualize regional cerebral perfusion.
As a legacy diagnostic radiopharmaceutical nearing loss of exclusivity, the brand faces declining market opportunity with likely consolidation of commercial teams and shift toward next-generation imaging agents.
Radiopharmaceutical Activity
Radioactive Diagnostic Agent
Working on CERETEC offers limited career growth opportunity as a mature, legacy diagnostic agent facing loss of exclusivity and portfolio cannibalization within GE HealthCare's own competitive landscape. Career professionals should consider this role primarily for maintaining stable diagnostic revenue streams or as a stepping stone to next-generation imaging platforms like CERIANNA.
Worked on CERETEC at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.